Patent application number | Description | Published |
20110237522 | NEUTRAL NANOTRANSPORTERS - Neutral lipid formulations for nucleic acid delivery are provided according to the invention. The neutral lipid formulations include hydrophobically modified polynucleotides and fat mixtures. Methods of using the neutral lipid formulations are also provided. | 09-29-2011 |
20110237648 | RNA INTERFERENCE IN SKIN INDICATIONS - The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications. | 09-29-2011 |
20110263680 | REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS - The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators. | 10-27-2011 |
20120040459 | REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS - The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. | 02-16-2012 |
20120059046 | INHIBITION OF MAP4K4 THROUGH RNAI - RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities, and uses thereof are disclosed. The blunt-ended constructs have a double-stranded region of 19-49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the strands may be modified (e.g., one or both ends of the sense strand is modified by 2′-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, the antisense strand may also be modified by a 2′-O-methyl group at the penultimate 5′-end nucleotide to greatly reduce off-target silencing. | 03-08-2012 |
20120065243 | RNA DUPLEXES WITH SINGLE STRANDED PHOSPHOROTHIOATE NUCLEOTIDE REGIONS FOR ADDITIONAL FUNCTIONALITY - The present invention relates to RNAi constructs and their use in gene silencing. RNAi constructs associated with the invention contain a double stranded region connected to a single stranded region of phosphorothioate modified nucleotides. | 03-15-2012 |
20130131141 | REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS - The present invention relates to methods for in vivo administration of sd-rxRNA molecules. | 05-23-2013 |
20130131142 | RNA INTERFERENCE IN OCULAR INDICATIONS - The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules. | 05-23-2013 |
20130197055 | INHIBITION OF PCSK9 THROUGH RNAI - The invention relates to various PCSK9 RNAi constructs with gene silencing activities, and uses thereof The construct has a double-stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity The sense strand may be modified such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC In addition, the antisense strand may also be modified by 2′-O-methyl groups at the 2nd 5′-end nucleotide to greatly reduce off-target silencing The constructs of the invention largely avoid the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity. | 08-01-2013 |
20140113950 | INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS - The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications. | 04-24-2014 |
20140315974 | RNA INTERFERENCE IN SKIN INDICATIONS - The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications. | 10-23-2014 |
20140364482 | REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS - The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. | 12-11-2014 |
Patent application number | Description | Published |
20110039914 | MODIFIED RNAI POLYNUCLEOTIDES AND USES THEREOF - The invention relates to improved RNAi constructs and uses thereof. The construct has a double stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the sense strand may be modified (e.g., one or both ends of the sense strand is/are modified by four 2′-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC. In addition, the antisense strand may also be modified by 2′-O-methyl group at the 2nd 5′-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoids the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity. | 02-17-2011 |
20110160285 | IDENTIFICATION OF MIRNA PROFILES THAT ARE DIAGNOSTIC OF HYPERTROPHIC CARDIOMYOPATHY - Disclosed herein are a collection of miRNAs and genes whose expression is altered in hypertrophic cardiomyopathy. Accordingly, these miRNAs and genes, singly or in combination, are useful as molecular markers for diagnosis or prognosis of hypertrophic cardiomyopathy. The miRNAs and genes disclosed can also be therapeutic targets for cardiac hypertrophy. For example, agents such as miRNA mimics, miRNA inhibitors or siRNAs for a given miRNA or gene can be used to modulate the level of these molecules thereby inhibiting or preventing hypertrophic cardiomyopathy. | 06-30-2011 |
20110172289 | MINOR GROOVE BINDER (MGB)-OLIGONUCLEOTIDE MIRNA ANTAGONISTS - Compositions and methods for inhibiting the actions of non-coding RNAs such as miRNAs and piRNAs are provided. The compositions comprise single or double stranded oligonucleotides conjugated with Minor Groove Binders (“MGBs”). The oligonucleotides can vary in length, can contain nucleotides having one or more modifications, and have regions that are substantially complementary to one or more mature miRNAs or piRNAs. | 07-14-2011 |
20110251258 | RNAI CONSTRUCTS AND USES THEREOF - The invention relates to improved double-stranded RNAi constructs (sometimes referred to as “solo-rxRNA”) and uses thereof. The construct comprises a structure formed in some aspects of the invention by two identical single-stranded polynucleotides, with the structure having two double-stranded stem regions (each having less than 21 base pairs) and a loop or bulge having about 4 to 11 nucleotides on each strand. The construct is resistant to cleavage by Dicer or other Dicer-like RNase III enzymes and is capable of being loaded into a RISC complex to effect RNA interference. In addition, the nucleotides of the present hairpin constructs may be modified to greatly enhance functionality, such as stability and specificity. | 10-13-2011 |
20120065250 | siRNA Targeting Apolipoprotein B (APOB) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB. | 03-15-2012 |
20120220496 | siRNA Targeting Catenin, Beta-1 (CTNNB1) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CTNNB1. | 08-30-2012 |
20120252873 | siRNA Targeting Interleukin-1 Receptor-associated Kinase 4 (IRAK4) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for IRAK4. | 10-04-2012 |
20120258888 | siRNA Targeting Proto-oncogene MET - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MET. | 10-11-2012 |
20120258889 | siRNA Targeting Kinase Insert Domain Receptor (KDR) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for KDR. | 10-11-2012 |
20120259001 | Duplex Oligonucleotides with Enhanced Functionality in Gene Regulation - Disclosed are methods of enhancing functionality of duplex oligonucleotides and compositions made by the methods. The duplex oligonucleotides include siRNAs, miRNA mimics, and piRNA mimics which contain modified nucleotides and mismatches between the two strands of the molecule at specific nucleotide positions. | 10-11-2012 |
20120264813 | siRNA Targeting Cyclin-dependent Kinase Inhibitor 1B (p27, Kip1) (CDKN1B) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B. | 10-18-2012 |
20120270751 | siRNA Targeting Diacylglycerol O-Acyltransferase Homolog 2 (DGAT2) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for DGAT2. | 10-25-2012 |
20120270926 | siRNA Targeting Apoliprotein (APOB) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB. | 10-25-2012 |
20120283142 | siRNA Targeting Amyloid Beta (A4) Precursor Protein (APP) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APP. | 11-08-2012 |
20120283311 | siRNA Targeting Glucagon Receptor (GCCR) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for GCGR. | 11-08-2012 |
20120322855 | Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference - Provided herein are duplex oligonucleotide complexes which can be administered to a cell, tissue or organism to silence a target gene without the aid of a transfection reagent(s). The duplex oligonucleotide complexes of the disclosure include a conjugate moiety that facilitates delivery to a cell, tissue or organism. | 12-20-2012 |
20130023446 | siRNA Targeting Beta Secretase (BACE) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for BACE. | 01-24-2013 |
20130059760 | siRNA Targeting Fructose-1, 6-bisphosphatase 1 (FBP1) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for FBP1. | 03-07-2013 |
20130210676 | siRNA Targeting Myeloid Differentiation Primary Response Gene (88) (MYD88) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MYD88. | 08-15-2013 |
20130225447 | siRNA Targeting Apolipoprotein B (APOB) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APOB. | 08-29-2013 |
20130225667 | siRNA Targeting Cyclin-dependent Kinase Inhibitor 1B (p27, Kip1) (CDKN1B) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B. | 08-29-2013 |
20140094390 | siRNA Targeting TIE-2 - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed. | 04-03-2014 |
20140148362 | Methods and Compositions for Selecting siRNA of Improved Functionality - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TTR. | 05-29-2014 |
20140336242 | Micro-RNA Scaffolds and Non-naturally Occurring Micro-RNAs - The present disclosure provides a non-naturally occurring miRNA having a stem-loop structure comprising a scaffold derived from a first endogenous miRNA (e.g., miR-196a-2 or miR-204), a mature strand derived from a second endogenous miRNA, and a star strand sequence that is at least partially complementary to the mature strand sequence. The present disclosure also provides a non-naturally occurring miRNA having a stem-loop structure comprising a scaffold derived from an endogenous miRNA (e.g., miR-196a-2 or miR-204), a mature strand designed to be at least partially complementary to a target RNA, and a star strand sequence that is at least partially complementary to the mature strand sequence. The methods and compositions of the disclosure may be used to mediate gene silencing via the RNAi pathway. | 11-13-2014 |
20140343130 | Micro-RNA Scaffolds, Non-naturally Occurring Micro-RNAs, and Methods for Optimizing Non-naturally Occurring Micro-RNAs - The present disclosure provides non-naturally occurring miR-196a-2 miRNAs and non-naturally occurring miR-204 miRNAs. The non-naturally occurring miRNAs of the disclosure have mature strand sequences distinct from their endogenous counterparts. The disclosure also provides methods of selecting mature strand sequences that function optimally in non-naturally occurring miR-196a-2 miRNAs. The methods and compositions of the disclosure may be used to mediate gene silencing via the RNAi pathway. | 11-20-2014 |
Patent application number | Description | Published |
20100082604 | AUTOMATIC SEARCH QUERY SUGGESTIONS WITH SEARCH RESULT SUGGESTIONS FROM USER HISTORY - Suggested search results are provided with suggested search queries as a user incrementally enters characters of a search query. At each incremental user input, a query portion is received and suggested search queries are identified based on the query portion. Suggested search results associated with the suggested search queries are also identified. These suggested search results enable direct navigation to web sites associated with the search results. In some embodiments, a user's search history is analyzed to identify search results selected by the user for the suggested search queries. In other embodiments, search histories for a group of users associated with the user are analyzed to identify the suggested search results to provide with the suggested search queries. | 04-01-2010 |
20120123673 | GENERATING A MAP THAT INCLUDES LOCATION AND PRICE OF PRODUCTS IN A SHOPPING LIST - Described herein are technologies pertaining to presenting a map to a user that comprises graphical icons that are representative of retail stores. The user has provided a shopping list, wherein the shopping list includes a plurality of products that are desirably purchased by the user. Inventories of retail stores in a geographic region of interest to the user are searched, and a map is generated that includes graphical icons representative of the retail stores, data that indicates that product(s) in the shopping list are available at the retail stores, and price data that indicates prices of product(s) in the shopping list at the respective retail stores. | 05-17-2012 |
20120123674 | DISPLAYING PRODUCT RECOMMENDATIONS ON A MAP - Described herein are technologies pertaining to presenting a map to a user that comprises graphical icons that are representative of retail stores. The user has performed a search for a product, wherein the product has a parameter corresponding thereto, and the parameter has a constraint corresponding thereto. Inventories of multiple retail stores can be searched over by relaxing the constraint, thereby allowing a recommended product to be located. A graphical icon representative of a retail store that has the recommended product in stock is included in the map together with data indicative of the price of the recommended product at the retail store. | 05-17-2012 |
20130083079 | DYNAMIC DISPLAY OF ICONS ON A SMALL SCREEN - Where a label for an item to be represented by an icon is customized, the icon is generated to dynamically display all of the label. Thus, at some point, the entire label is displayed, even though only a portion of the label is eventually displayed in the icon. | 04-04-2013 |
20130241852 | USE OF TOUCH AND GESTURES RELATED TO TASKS AND BUSINESS WORKFLOW - A business data system generates a user interface display showing a business data record. The business data system receives a touch gesture user input to manipulate the business data record to perform an operation, a task or a workflow within the business data system. The business data system performs the operation, task or workflow based on the touch gesture user input. | 09-19-2013 |
20130241951 | MULTIMODAL LAYOUT AND RENDERING - A layout transformation system accesses application metadata that defines a plurality of different structures for displaying components of the application, based upon the particular modality of the display device. The layout transformation system then transforms a user interface display based on the application metadata and based upon the particular modality, and provides the user interface display to the display device for rendering and user interaction. | 09-19-2013 |
20130246111 | USE OF TOUCH AND GESTURES RELATED TO TASKS AND BUSINESS WORKFLOW - A business data system generates a user interface display showing a business data record. The business data system receives a touch gesture user input to manipulate the business data record to perform an operation, a task or a workflow within the business data system. The business data system performs the operation, task or workflow based on the touch gesture user input. | 09-19-2013 |
20130246913 | USE OF TOUCH AND GESTURES RELATED TO TASKS AND BUSINESS WORKFLOW - A business data system generates a user interface display showing a business data record. The business data system receives a touch gesture user input to manipulate the business data record to perform an operation, a task or a workflow within the business data system. The business data system performs the operation, task or workflow based on the touch gesture user input. | 09-19-2013 |
20130246930 | TOUCH GESTURES RELATED TO INTERACTION WITH CONTACTS IN A BUSINESS DATA SYSTEM - A business data system generates a user interface display showing a business data record. The business data system receives a touch gesture user input manipulating a contact within the business data system. The business data system manipulates the contact based on the touch gesture user input. | 09-19-2013 |
20140059498 | USER INTERFACE DISPLAY OF ANCHOR TILES FOR RELATED ENTITIES - A display is generated for displaying entities that are related to a selected entity. The display includes one or more tiles, each tile displaying a representation of a selected entity and associated entities, within that single tile. | 02-27-2014 |
20140089853 | DYNAMIC DISPLAY OF ICONS ON A SMALL SCREEN - Where a label for an item to be represented by an icon is customized, the icon is generated to dynamically display all of the label. Thus, at some point, the entire label is displayed, even though only a portion of the label is eventually displayed in the icon. | 03-27-2014 |
20140365511 | FILTERING CONTENT ON A ROLE TAILORED WORKSPACE - A workspace display includes a plurality of different groups, each group including a plurality of different components. Each group corresponds to a task, set of tasks or topic of information related to a user's role. The particular components included in each group are user interface display elements that are each related to an item of content within the corresponding group. The workspace display has filter mechanisms that are actuated to filter the content displayed in the components on the workspace display. | 12-11-2014 |
20140365939 | DISPLAYING DIFFERENT VIEWS OF AN ENTITY - An entity hub display includes a plurality of different sections, each section including a plurality of different components. The sections each correspond to a different aspect of data that makes up an entity. Each component is a user interface display element that is related to data within the corresponding section. The individual components can be selected and placed on the entity hub display based on a user's role and activities or tasks performed by a user in that role. | 12-11-2014 |
20140365952 | NAVIGATION AND MODIFYING CONTENT ON A ROLE TAILORED WORKSPACE - A user interface is displayed that has one or more workspace display sectors, based on a user role. Each workspace display selector corresponds to a given workspace display. A workspace display includes a plurality of different groups, each group including a plurality of different components. Each group corresponds to a task, set of tasks or topic of information related to a user's role. The particular components included in each group are user interface display elements that are each related to an item of content within the corresponding group. | 12-11-2014 |
Patent application number | Description | Published |
20090044820 | Stencils and gauging device for aesthetically pleasing eyebrow shaping - A novel gauging device and associated stencils facilitate the shaping of eyebrows according to a Golden Ratio standard. The gauging device is adapted to be placed over a woman's face and maintained in a fixed position relative to her eyes and nose. A nosepiece and knobs are adjusted such that a lower end of a guide rod may be rotated about various points relative to the nose and held in predetermined angles relative to the nose and eyes, possibly supported magnetically on a lower track adjacent the nostrils and an upper track above the eyebrows. An eyebrow stencil is held in a desired position relative to the previously positioned guide rod, which facilitates convenient application and symmetrical shaping, preferably with frictional clamps for permitting the stencil to be shifted in place so that a particular portion of the stencil is properly aligned with the guide rod after the guide rod has been aligned with an appropriate Golden Ratio marking on the stencil. Each stencil may be provided with more than one set of such markings to accommodate not only different eyebrows of different sizes, but also to adjust the eyebrow's ideal Golden Ratio “High Point” to complement facial proportions (preferably represented by a single Facial Ratio Value or “FRV” that takes into account several different measured ratios) that deviate substantially from an ideal Golden Ratio. A slim tab between the upper and the lower edges of the stencil cut-out preferably provides a convenient reference mark for the “High Point” of the unadjusted cut-out. | 02-19-2009 |
20120222694 | STENCILS AND GAUGING DEVICE FOR AESTHETICALLY PLEASING EYEBROW SHAPING - A novel gauging device and associated stencils facilitate the shaping of eyebrows according to a Golden Ratio standard. The gauging device is adapted to be placed over a woman's face and maintained in a fixed position relative to her eyes and nose. A nosepiece and knobs are adjusted such that a lower end of a guide rod may be rotated about various points relative to the nose and held in predetermined angles relative to the nose and eyes, possibly supported magnetically on a lower track adjacent the nostrils and an upper track above the eyebrows. An eyebrow stencil is held in a desired position relative to the previously positioned guide rod, which facilitates convenient application and symmetrical shaping, preferably with frictional clamps for permitting the stencil to be shifted in place so that a particular portion of the stencil is properly aligned with the guide rod after the guide rod has been aligned with an appropriate Golden Ratio marking on the stencil. Each stencil may be provided with more than one set of such markings to accommodate not only different eyebrows of different sizes, but also to adjust the eyebrow's ideal Golden Ratio “High Point” to complement facial proportions (preferably represented by a single Facial Ratio Value or “FRV” that takes into account several different measured ratios) that deviate substantially from an ideal Golden Ratio. A slim tab between the upper and the lower edges of the stencil cut-out preferably provides a convenient reference mark for the “High Point” of the unadjusted cut-out. | 09-06-2012 |
20130098385 | Eyebrow Stencil Holder - A novel gauging device and associated stencils facilitate the shaping of eyebrows according to a Golden Ratio standard. The gauging device is adapted to be placed over a woman's face and maintained in a fixed position relative to her eyes and nose. A nosepiece and knobs are adjusted such that a lower end of a guide rod may be rotated about various points relative to the nose and held in predetermined angles relative to the nose and eyes, possibly supported magnetically on a lower track adjacent the nostrils and an upper track above the eyebrows. An eyebrow stencil is held in a desired position relative to the previously positioned guide rod, which facilitates convenient application and symmetrical shaping, preferably with frictional clamps for permitting the stencil to be shifted in place so that a particular portion of the stencil is properly aligned with the guide rod after the guide rod has been aligned with an appropriate Golden Ratio marking on the stencil. Each stencil may be provided with more than one set of such markings to accommodate not only different eyebrows of different sizes, but also to adjust the eyebrow's ideal Golden Ratio “High Point” to complement facial proportions (preferably represented by a single Facial Ratio Value or “FRV” that takes into account several different measured ratios) that deviate substantially from an ideal Golden Ratio. A slim tab between the upper and the lower edges of the stencil cut-out preferably provides a convenient reference mark for the “High Point” of the unadjusted cut-out. | 04-25-2013 |
20130306091 | Method of Using an Eyebrow Stencil Holder - A novel gauging device and associated stencils for shaping of eyebrows according to a Golden Ratio standard. The gauging device is adapted to be placed over a woman's face and maintained in a fixed position relative to her eyes and nose. A nosepiece and knobs are adjusted such that a lower end of a guide rod may be rotated about various points relative to the nose and held in predetermined angles relative to the nose and eyes, possibly supported magnetically on a lower track adjacent the nostrils and an upper track above the eyebrows. Each stencil may be adapted to accommodate not only different eyebrows of different sizes, but also to adjust the eyebrow's ideal Golden Ratio “High Point” to complement facial proportions (preferably represented by a single Facial Ratio Value or “FRV”) that deviate from an ideal Golden Ratio. | 11-21-2013 |
20140144457 | Method of Shaping Eyebrows - A novel gauging device and associated stencils for shaping of eyebrows according to a Golden Ratio standard. The gauging device is adapted to be placed over a woman's face and maintained in a fixed position relative to her eyes and nose. A nosepiece and knobs are adjusted such that a lower end of a guide rod may be rotated about various points relative to the nose and held in predetermined angles relative to the nose and eyes, possibly supported magnetically on a lower track adjacent the nostrils and an upper track above the eyebrows. Each stencil may be adapted to accommodate not only different eyebrows of different sizes, but also to adjust the eyebrow's ideal Golden Ratio “High Point” to complement facial proportions (preferably represented by a single Facial Ratio Value or “FRV” that deviate from an ideal Golden Ratio. | 05-29-2014 |
20140311514 | Eyebrow Stencil Holder - A novel gauging device and associated stencils facilitate the shaping of eyebrows according to a Golden Ratio standard. The gauging device is adapted to be placed over a woman's face and maintained in a fixed position relative to her eyes and nose. A nosepiece and knobs are adjusted such that a lower end of a guide rod may be rotated about various points relative to the nose and held in predetermined angles relative to the nose and eyes, possibly supported magnetically on a lower track adjacent the nostrils and an upper track above the eyebrows. An eyebrow stencil is held in a desired position relative to the previously positioned guide rod, which facilitates convenient application and symmetrical shaping, preferably with frictional clamps for permitting the stencil to be shifted in place so that a particular portion of the stencil is properly aligned with the guide rod after the guide rod has been aligned with an appropriate Golden Ratio marking on the stencil. Each stencil may be provided with more than one set of such markings to accommodate not only different eyebrows of different sizes, but also to adjust the eyebrow's ideal Golden Ratio “High Point” to complement facial proportions (preferably represented by a single Facial Ratio Value or “FRV” that takes into account several different measured ratios) that deviate substantially from an ideal Golden Ratio. A slim tab between the upper and the lower edges of the stencil cut-out preferably provides a convenient reference mark for the “High Point” of the unadjusted cut-out. | 10-23-2014 |
20150101629 | GOLDEN RATIO EYEBROW SHAPING METHOD - An eyebrow shaping method includes providing an image of a face. Three guidelines are determined on the image and thee points are located via the guidelines. An eyebrow is shaped to have Golden Ration proportions via the three points. | 04-16-2015 |
20150189968 | Golden Ratio Eyebrow Shaping Method - An eyebrow shaping method includes providing an image of a face. Three guidelines are determined on the image and thee points are located via the guidelines. An eyebrow is shaped to have Golden Ration proportions via the three points. | 07-09-2015 |
Patent application number | Description | Published |
20080318899 | Pyridazine Compounds, Compositions and Methods - The invention relates to novel chemical compounds and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications. | 12-25-2008 |
20120245125 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS - The invention relates to novel chemical compounds, compositions and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of making and using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for, research, drug screening, and therapeutic applications. | 09-27-2012 |
20150175555 | PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS - The invention relates to novel chemical compounds, compositions and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of making and using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications. | 06-25-2015 |